1.
Kardiologiia
; 32(3): 48-50, 1992 Mar.
Artigo
em Russo
| MEDLINE
| ID: mdl-1383590
RESUMO
The antiarrhythmic agent mexicord (Polfa, Poland) versus ethmozine underwent a clinical trial. Meticord was found to have a marked antiarrhythmic effect and be useful in the long-term management of patients with ventricular tachyarrhythmias.